Clinical Research Directory
Browse clinical research sites, groups, and studies.
Assess the Safety, Tolerability, and Pharmacokinetics of HL-1186 in Healthy Participants
Sponsor: Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
Summary
This single-center, randomized, double-blind, placebo-controlled, two-part study is designed to assess the safety, tolerability and PK of oral HL-1186 Tablet in healthy participants.
Official title: A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of HL-1186 in Healthy Participants
Key Details
Gender
All
Age Range
18 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
76
Start Date
2025-03-21
Completion Date
2025-10-09
Last Updated
2025-08-24
Healthy Volunteers
Yes
Conditions
Interventions
HL-1186
HL-1186 tablet for oral administration.
HL-1186 placebo
HL-1186 placebo tablet for oral administration.
Locations (1)
Jiangnan University Affiliated Hospital
Wuxi, China